Leptomeningeal carcinomatosis from renal cell cancer: treatment attempt with radiation and sunitinib (case report)
© Dalhaug et al; licensee BioMed Central Ltd. 2010
Received: 4 January 2010
Accepted: 5 May 2010
Published: 5 May 2010
A case of leptomeningeal carcinomatosis in a patient with known brain and lung metastases from renal cell cancer without previous systemic therapy is presented. Neoplastic meningitis (NM) developed 31 months after first diagnosis of simultaneous extra- and intracranial recurrence of kidney cancer and surgical resection of a cerebellar metastasis. In spite of local radiotherapy to the macroscopic NM lesions in the cervical and lumbar spine followed by initiation of sunitinib, the patient succumbed to his disease 4 months after the diagnosis of NM. The untreated lung metastases progressed very slowly during almost 3 years of observation. This case illustrates important issues around both biological behaviour and treatment approaches in metastatic renal cell cancer.
Brain metastases from renal cell carcinoma might develop many years after primary nephrectomy and continue to represent a formidable challenge . With increasing numbers of local and systemic treatment options, the issue of patient selection gains importance. While surgery and stereotactic radiosurgery (SRS) provide long-term local control of macroscopic disease, development of new central nervous system lesions can often be observed. Some patients might even present with leptomeningeal carcinomatosis or so called neoplastic meningitis (NM). Only few cases of NM from renal cell carcinoma treated with contemporary systemic approaches have been reported [2, 3]. Therefore, the present case illustrates important aspects around potential treatment options.
NM from renal cell carcinoma is a rare event, with only few cases reported to date [2, 3]. In the present patient, it was preceded by brain metastases, initially a single cerebellar lesion, which was surgically removed. Whether resection of posterior fossa metastases increases the risk of leptomeningeal dissemination is a topic of debate. Recent data suggest that en bloc removal of metastatic lesions does not increase the risk . Fractionated external beam radiotherapy might offer symptom palliation in patients with brain metastases from kidney cancer . Median survival was 3 months. Median survival and long-term survival rates are higher in patients treated with surgical resection or SRS. In a series of 32 patients, SRS resulted in median survival of 10 months and 3-year survival of 16% . A large analysis including more than 1000 patients treated with SRS without additional whole-brain radiotherapy (WBRT) showed that approximately 50% developed new lesions (several types of primary tumors were included) . Comparable findings were made in surgery series. The addition of WBRT to either SRS or surgical resection decreased the in-brain failure rates but failed to improve survival, most likely because new lesions can be treated with salvage SRS or surgery [8–10]. It has been argued that delaying WBRT may be appropriate for some subgroups of patients with SRS-treated brain metastases from renal cell carcinoma and other relatively radioresistant tumors . As these subgroups are not well defined, individual discussion and decision is necessary. In the present case, no postoperative radiotherapy was administered. Instead, salvage SRS was given to the sites of intracranial relapse. A previous study included analyses of the impact of systemic treatment on survival. Systemic immunotherapy with interleukin-2 and interferon was associated with improved 3-year survival, while treatment with antiangiogenic agents was not . Nevertheless, antiangiogenic agents have become a mainstay of treatment in the general population of patients with metastatic renal cell carcinoma and occasional responses of brain metastases to these drugs have been reported . In another series with 138 renal cell carcinoma patients with brain metastases, 5-year survival was 12% , suggesting that aggressive management should be considered in prognostically favorable patients.
Surgical resection should be considered in patients with renal cell carcinoma developing metachronous lung metastases , but in the present case bilateral lesions and mediastinal lymph node metastases were detected. In addition, the diagnosis of brain metastasis argued against lung surgery. The untreated lung and lymph node lesions progressed very slowly (Figure 2), a finding not uncommon in this disease. Nevertheless, these metastases might have been the source of further dissemination. The slow growth rate and absence of clinical symptoms prompted the treating oncologists to postpone systemic therapy. This decision was also influenced by the potential serious toxicity of systemic therapy. If tailored to the clinical symptoms, systemic therapy would not have been necessary before the almost simultaneous detection of leptomeningeal and bone metastases. However, at that time careful consideration of treatment options was necessary. It was felt that radiotherapy to the macroscopic spinal lesions was more appropriate than to the complete craniospinal axis, both with regard to reduced bone marrow toxicity and treatment time. The aim was to avoid delays in systemic therapy or reduced doses because of neutro- and/or thrombopenia. Intrathecal chemotherapy should be considered in patients with NM from breast cancer or hematologic malignancies. In patients with renal cell carcinoma, its role is less well defined.
Sunitinib, which is currently used as first-line treatment in patients with metastatic renal cell carcinoma in Norway, resulted in median progression-free survival of 10.8 months in a large trial where 375 patients received the drug . Its role in patients with limited performance status and/or central nervous system metastases is not well defined and requires additional studies. We are not aware of clinical data supporting its use in patients with NM. The patient presented here developed both hematologic and infectious complications after 2 weeks on sunitinib and treatment was then discontinued. In addition, the patient's general condition deteriorated slowly. Eventually, he died from pneumonia. Survival after NM was 4 months. This figure is comparable to data in mixed patient groups (breast cancer, lymphoma, lung cancer etc.), where those with KPS 70 or greater had median survival of 15.5 weeks and those with KPS <70 only 6 weeks . The presence or absence of CSF cytology did not influence survival . Overall, NM is often associated with extensive extracranial disease burden and short survival in spite of treatment with radio- and chemotherapy . Performance status and extent of disease should guide the choice of treatment . Studying the role of renal cell carcinoma-specific systemic treatment approaches requires collaborative efforts because NM is a rare event is this particular disease.
Written informed consent was obtained from the patient's relative for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Cimatti M, Salvati M, Caroli E, Frati A, Brogna C, Gagliardi FM: Extremely delayed cerebral metastasis from renal carcinoma: report of 4 cases and critical analysis of the literature. Tumori. 2004, 90: 342-344.PubMedGoogle Scholar
- Ranze O, Hofmann E, Distelrath A, Hoeffkes HG: Renal cell cancer presented with leptomeningeal carcinomatosis effectively treated with sorafenib. Onkologie. 2007, 30: 450-451. 10.1159/000105131.View ArticlePubMedGoogle Scholar
- Tippin DB, Reeves W, Vogelzang NJ: Diagnosis and treatment of leptomeningeal metastases in a patient with renal carcinoma responding to 5-fluorouracil and gemcitabine. J Urol. 1999, 162: 155-156. 10.1097/00005392-199907000-00038.View ArticlePubMedGoogle Scholar
- Suki D, Abouassi H, Patel AJ, Sawaya R, Weinberg JS, Groves MD: Comparative risk of leptomeningeal disease after resection or stereotactic radiosurgery for solid tumor metastasis to the posterior fossa. J Neurosurg. 2008, 108: 248-257. 10.3171/JNS/2008/108/2/0248.View ArticlePubMedGoogle Scholar
- Cannady SB, Cavanaugh KA, Lee SY, Bukowski RM, Olencki TE, Stevens GH, Barnett GH, Suh JH: Results of whole brain radiotherapy and recursive partitioning analysis in patients with brain metastases from renal cell carcinoma: a retrospective study. Int J Radiat Oncol Biol Phys. 2004, 58: 253-258. 10.1016/S0360-3016(03)00818-6.View ArticlePubMedGoogle Scholar
- Samlowski WE, Majer M, Boucher KM, Shrieve AF, Dechet C, Jensen RL, Shrieve DC: Multidisciplinary treatment of brain metastases derived from clear cell renal cancer incorporating stereotactic radiosurgery. Cancer. 2008, 113: 2539-2548. 10.1002/cncr.23857.View ArticlePubMedGoogle Scholar
- Serizawa T, Higuchi Y, Ono J, Matsuda S, Nagano O, Iwadate Y, Saeki N: Gamma knife surgery for metastatic brain tumors without prophylactic whole-brain radiotherapy: results in 1000 consecutive cases. J Neurosurg. 2006, 105 (Suppl): 86-90.PubMedGoogle Scholar
- Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, Kenjyo M, Oya N, Hirota S, Shioura H, Kunieda E, Inomata T, Hayakawa K, Katoh N, Kobashi G: Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases. A randomized controlled trial. JAMA. 2006, 295: 2483-2491. 10.1001/jama.295.21.2483.View ArticlePubMedGoogle Scholar
- Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, Markesbery WR, Foon KA, Young B: Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA. 1998, 80: 1485-1489. 10.1001/jama.280.17.1485.Google Scholar
- Nieder C, Astner ST, Grosu AL, Andratschke NH, Molls M: The role of postoperative radiotherapy after resection of a single brain metastasis: combined analysis of 643 patients. Strahlenther Onkol. 2007, 183: 576-580. 10.1007/s00066-007-1756-4.View ArticlePubMedGoogle Scholar
- Manon R, O'Neill A, Knisely J, Werner-Wasik M, Lazarus HM, Wagner H, Gilbert M, Metha M, Eastern Cooperative Oncology Group: Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma: an Eastern Cooperative Oncology Group study (E 6397). J Clin Oncol. 2005, 23: 8870-8876. 10.1200/JCO.2005.01.8747.View ArticlePubMedGoogle Scholar
- Koutras AK, Krikelis D, Alexandrou N, Starakis I, Kalofonos HP: Brain metastasis in renal cell cancer responding to sunitinib. Anticancer Res. 2007, 27: 4255-4257.PubMedGoogle Scholar
- Shuch B, La Rochelle JC, Klatte T, Riggs SB, Liu W, Kabbinavar FF, Pantuck AJ, Belldegrun AS: Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival. Cancer. 2008, 113: 1641-1648. 10.1002/cncr.23769.View ArticlePubMedGoogle Scholar
- Hofmann HS, Neef H, Krohe K, Andreev P, Silber RE: Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. Eur Urol. 2005, 48: 77-81. 10.1016/j.eururo.2005.03.004.View ArticlePubMedGoogle Scholar
- Motzer RJ, Bukowski RM, Figlin RA, Hutson TE, Michaelson MD, Kim ST, Baum CM, Kattan MW: Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer. 2008, 113: 1552-1558. 10.1002/cncr.23776.View ArticlePubMedGoogle Scholar
- Chamberlain MC, Johnston SK, Glantz MJ: Neoplastic meningitis-related prognostic significance of the Karnofsky performance status. Arch Neurol. 2009, 66: 74-78. 10.1001/archneurol.2008.506.PubMedGoogle Scholar
- Chamberlain MC, Johnston SK: Neoplastic meningitis: survival as a function of cerebrospinal fluid cytology. Cancer. 2009, 115: 1941-1946. 10.1002/cncr.24210.View ArticlePubMedGoogle Scholar
- Shapiro WR, Johanson CE, Boogerd W: Treatment modalities for leptomeningeal metastases. Semin Oncol. 2009, 36: S46-54. 10.1053/j.seminoncol.2009.05.006.View ArticlePubMedGoogle Scholar
- Chamberlain MC: Neoplastic meningitis. Oncologist. 2008, 13: 967-977. 10.1634/theoncologist.2008-0138.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.